Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in:

03.08.2020 | Breast Oncology

Clinical Factors Affecting the Therapeutic Efficacy of Evening Primrose Oil on Mastalgia

verfasst von: Fatih Levent Balci, MD, Cihan Uras, MD, Sheldon Feldman, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Saturated fatty acid esters may cause mastalgia via hypersensitivity of breast epithelium to circulating hormones. Evening primrose oil (EPO) may restore the saturated/unsaturated fatty acid balance and decrease sensitivity to steroidal hormones or prolactin. Conflicting results exist regarding EPO treatment for mastalgia. The aim of this study was to determine the effectiveness of EPO and factors affecting its efficacy in treatment of mastalgia.

Methods

The study included 1015 patients, ages 14–82 (mean age 42.21 ± 10.8), admitted to Acibadem Breast Clinic between January 2015 and March 2018. The patients were divided into group I (n = 581) treated with EPO (1300 mg, twice a day) and group II (n = 434) treated with paracetamol (500 mg, twice a day). The visual analog scale was used to assess EPO’s therapeutic efficacy, compared with paracetamol, measured at admittance, 2 weeks, and 6 weeks. Clinical factors affecting the efficacy of EPO were analyzed.

Results

The therapeutic efficacy of EPO on mastalgia was significantly higher than with paracetamol (p < 0.001). Factors significantly affecting the efficacy of EPO treatment were hormone replacement therapy (HRT), IUD-with-levonorgestrel, iron deficiency, overt hypothyroidism, and Hashimoto thyroiditis (p < 0.01). Replacement of iron or thyroid hormone efficiently treated mastalgia in patients that did not respond to EPO treatment. Side effects (allergy, anxiety, blurred vision, constipation, and nausea) were rare and not statistically significant (p = 0.88).

Conclusion

EPO can be used in the treatment of mastalgia without significant side effects. HRT, IUD-with-levonorgestrel, iron deficiency, overt hypothyroidism, and Hashimoto thyroiditis significantly affect the efficacy of EPO on mastalgia.
Literatur
1.
Morrow M. The evaluation of common breast problems. Am Fam Phys. 2000;61(8):2371–8.PubMed
2.
Pruthi S, Wahner-Roedler DL, Torkelson CJ, et al. Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study. Altern Med Rev. 2010;15(1):59–67.PubMed
3.
Gateley CA, Maddox PR, Pritchard GA, et al. Plasma fatty acid profiles in benign breast disorders. Br J Surg. 1992;79(5):407–409.PubMed
4.
Blommers J, de Lange-De Klerk ES, Kuik DJ, et al. Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial. Am J Obstet Gynecol. 2002;187:1389–1394.PubMed
5.
Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomised trials. Breast. 2007;16:503–512.PubMed
6.
Ader DN, Browne MW. Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. Am J Obstet Gynecol. 1997;177:126–132.PubMed
7.
Colak T, Ipek T, Kanik A, et al. Efficacy of topical nonsteroidal anti-inflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196 (4):525–530.PubMed
8.
Irving AD, Morrison SL. Effectiveness of topical non-steroidal anti-inflammatory drugs in the management of breast pain. J R Coll Surg Edinb. 1998;43 (3):158–159.PubMed
9.
Groen JW, Grosfeld S, Wilschut JA, et al. Cyclic and non-cyclic breast-pain: a systematic review on pain reduction, side effects, and quality of life for various treatments. Eur J Obstet Gynecol Reprod Biol. 2018;2017;219:74–93.
10.
Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomised trials. Breast. 2007;16(5):503–512.PubMed
11.
12.
Gately CA, Miers M, Mansel RE, Hughes LE. Drug treatments for mastalgia: 17 years experience in the Cardiff Mastalgia Clinic. J R Soc Med. 1992;85: 12–15.
13.
Horrobin DF, Manku MS. Premenstrual syndrome and premenstrual breast pain (cyclical mastalgia): disorders of essential fatty acid (EFA) metabolism. Prostaglandins Leukot Essent Fatty Acids Rev. 1989;37: 255–261.
14.
Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet. 1985;2(8451):373–377.PubMed
15.
Ingram DM, Hickling C, West L, Mahe LJ, Dunbar PM. A double-blind randomized controlled trial of isoflavones in the treatment of cyclical mastalgia. Breast. 2002;11:170–174.PubMed
16.
Pashby NL, Mansel RE, Hughes LE, et al. A clinical trial of evening primrose oil in mastalgia. Br J Surg. 1981;68:801.
17.
Preece PE, Baum M, Mansel RE, et al. Importance of mastalgia in operable breast cancer. Br Med J (Clin Res Ed). 1982;284:1299-1300.PubMedCentral
18.
Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197.
19.
Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet. 1985;2:373–377.PubMed
20.
McFayden IJ, Forrest AP, Chetty U, Raab G. Cyclical breast pain—some observations and the difficulties in treatment. Br J Clin Pract 1992;46:161–164.PubMed
21.
Cheung AN, Shen DH, Khoo US, et al. Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: correlation with mdm2, proliferation index, and clinicopathologic parameters. Int J Gynecol Cancer. 1999;9:123–130.PubMed
22.
Goyal A, Mansel RE, Efamast Study Group. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005;11:41-47.PubMed
23.
24.
Pearlman M, Griffin J, Swain M, Chelmow D. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice bulletin no. 164: Diagnosis and management of benign breast disorders. Obstet Gynecol. 2016;127(6):e141–e156.
25.
26.
Parveen S, Sarwar G, Ali M, Channa GA. Danazol versus oil of evening primrose in the treatment of mastalgia. Pak J Surg. 2007;23:10-13.
27.
Sharma N, Gupta A, Jha PK, Rajput P. Mastalgia cured! Randomized trial comparing centchroman to evening primrose oil. Breast J. 2012;18:509-510.PubMed
28.
Adamopoulos DA, Vassilaros S, Kapolla N, et al. Thyroid disease in patients with benign and malignant mastopathy. Cancer. 1986;57:125–128.PubMed
29.
Giustarini E, Pinchera A, Fierabracci P, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol. 2006;154:645–649.PubMed
30.
Venturi S. Is there a role for iodine in breast diseases? Breast. 2001;10:379–382.PubMed
31.
Ghent WR, Eskin BA, Low DA et al. Iodine replacement in fibrocystic disease of the breast. Can J Surg. 1993;36:453–460.PubMed
32.
Estes NC. Mastodynia due to fibrocystic disease of the breast controlled with thyroid hormone. Am J Surg. 1982;42:764–766.
33.
Bhargav PR, Mishra A, Agarwal G, et al. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. World J Surg. 2009;33(10):2087–2093.PubMed
34.
Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228–238.PubMed
35.
Vanderpump MP, Tunbridge WH, French JM. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 1995;43:55–68.PubMed
36.
Wilson GR, Curry RW. Subclinical thyroid disease. Am Fam Phys. 2005;72:1517–1524.PubMed
37.
Arrigo T, Wasniewska M, Crisafulli G, et al. Subclinical hypothyroidism: the state of the art. J Endocrinol Invest. 2009;31:79– 84.
38.
Bianco LE, Wiesinger J, Earley CJ, et al. Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague–Dawley rats. J Neurochem. 2008;106(1):205–215.PubMed
39.
Erikson KM, Jones BC, Hess EJ, et al. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav. 2001;69(3–4):409–418.PubMed
40.
Sen M, Kilic MO, Cemeroglu O, Icen D. Can mastalgia be another somatic symptom in fibromyalgia syndrome? Clinics (Sao Paulo). 2015;70(11):733–737.PubMedCentral
41.
Colegrave S, Holcombe C, Salmon P. Psychological characteristics of women presenting with breast pain. J Psychosom Res. 2001;50:303–307.PubMed
42.
Jenkins PL, Jamil N, Gateley C, Mansel RE. Psychiatric illness in patients with severe treatment-resistant mastalgia. Gen Hosp Psychiatry. 1993;15:55–57.PubMed
43.
Metadaten
Titel
Clinical Factors Affecting the Therapeutic Efficacy of Evening Primrose Oil on Mastalgia
verfasst von
Fatih Levent Balci, MD
Cihan Uras, MD
Sheldon Feldman, MD
Publikationsdatum
03.08.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08949-x

Weitere Artikel der Ausgabe 12/2020

Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers

  • Breast Oncology

Changing the Default: A Prospective Study of Reducing Discharge Opioid Prescription after Lumpectomy and Sentinel Node Biopsy

  • Breast Oncology

How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?

  • Breast Oncology

Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis

  • Breast Oncology

Adoption of Opioid-Sparing and Non-Opioid Regimens After Breast Surgery in a Large, Integrated Health Care Delivery System

  • Breast Oncology

Early Free Range-of-Motion Upper Limb Exercises After Mastectomy and Immediate Implant-Based Reconstruction Are Safe and Beneficial: A Randomized Trial

  • Breast Oncology

Neu im Fachgebiet Chirurgie

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Nackenschmerzen nach Bandscheibenvorfall: Muskeltraining hilft!

Bei hartnäckigen Schmerzen aufgrund einer zervikalen Radikulopathie schlägt ein Team der Universität Istanbul vor, lokale Steroidinjektionen mit einem speziellen Trainingsprogramm zur Stabilisierung der Nackenmuskulatur zu kombinieren.

US-Team empfiehlt Gastropexie nach Hiatushernien-Op.

Zur Vermeidung von Rezidiven nach Reparatur einer paraösophagealen Hiatushernie sollte einem US-Team zufolge der Magen bei der Op. routinemäßig an der Bauchwand fixiert werden. Das Ergebnis einer randomisierten Studie scheint dafür zu sprechen.

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise